Rusty Kelley, Ph.D., joined the Burroughs Wellcome Fund in 2013 to direct the translational and convergence initiatives. Prior to the Fund, Rusty held positions of increasing responsibility at Tengion, a biotech firm originating out of Wake Forest University, where as a senior scientist, director & then head of preclinical and a member of the leadership team, successfully helped lead the European & U.S. regulatory filings and secure private financing for developing first-in-human trials for novel regenerative engineering & medicine candidates. Rusty was previously in clinical development at PPD, Inc., where he directed phase I-III clinical trials in the divisions of Medicine, NIH trials and Infectious Disease. Prior to PPD, Rusty served on the bench in the pharmaceutics & analytical chemistry divisions for AAIPharma. Rusty received a BA in Chemistry from UNC Chapel Hill, a PhD in Pharmacology at LSU’s Health Sciences Center, was awarded an American Heart postdoc fellowship in cardiovascular and translational genomics at UNC Chapel Hill, and recently obtained an MBA from Duke University’s Fuqua School of Business.